MCID: HND002
MIFTS: 47

Hand, Foot and Mouth Disease malady

Categories: Skin diseases, Infectious diseases

Aliases & Classifications for Hand, Foot and Mouth Disease

Summaries for Hand, Foot and Mouth Disease

Disease Ontology : 12 A viral infectious disease that results_in infection located in skin, has material basis in Human coxsackievirus A16 or has material basis in Human enterovirus 71, which are transmitted_by contaminated fomites, and transmitted_by contact with nose and throat secretions, saliva, blister fluid and stool of infected persons. The infection has symptom fever, has symptom poor appetite, has symptom malaise, has symptom sore throat, has symptom painful sores in the mouth, and has symptom skin rash on the palms of the hands and soles of the feet.

MalaCards based summary : Hand, Foot and Mouth Disease, also known as vesicular stomatitis and exanthem, is related to mouth disease and herpangina, and has symptoms including fever, poor appetite and malaise. An important gene associated with Hand, Foot and Mouth Disease is SCARB2 (Scavenger Receptor Class B Member 2), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Apremilast and Sorafenib have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and brain.

CDC : 3 Hand, foot, and mouth disease is a common viral illness that usually affects infants and children younger than 5 years old. However, it can sometimes occur in older children and adults. Typical symptoms of hand, foot, and mouth disease include fever, mouth sores, and a skin rash.

Wikipedia : 71 Hand, foot and mouth disease (HFMD) is a common infection caused by a group of viruses. It typically... more...

Related Diseases for Hand, Foot and Mouth Disease

Diseases related to Hand, Foot and Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
id Related Disease Score Top Affiliating Genes
1 mouth disease 11.1
2 herpangina 10.4
3 ureter inverted papilloma 10.3 IL10 IL6
4 neonatal hypoxic and ischemic brain injury 10.3 IL10 IL6
5 childhood electroclinical syndrome 10.2 IL10 IL6
6 transient tic disorder 10.2 IL10 IL6
7 asymptomatic neurosyphilis 10.2 IFNG IL10
8 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.2 IFNG IL10
9 tungiasis 10.2 IFNG IL10
10 encephalitis 10.2
11 ciliary discoordination, due to random ciliary orientation 10.2 IFNG IL10
12 cataract, total congenital 10.2 IFNG IL6
13 plantar wart 10.2 IFNG IL10
14 centronuclear myopathy 5 10.2 IFNG IL10
15 schwannoma of ureter 10.2 CA6 IL6
16 discharging ear 10.2 IFNG IL10
17 esophagus lymphoma 10.2 IFNG IL6
18 hemangioma of spleen 10.1 IFNG IL6
19 cyclosporiasis 10.1 IFNG IL10 IL6
20 multiple mitochondrial dysfunctions syndrome 10.1 IFNG IL10 IL6
21 conduct disorder 10.1 IFNG IL10 IL6
22 pancreatic signet ring cell adenocarcinoma 10.1 IFNG IL10 IL6
23 ectodermal dysplasia bartalos type 10.1 IFNG IL10 IL6
24 hereditary alpha tryptasemia syndrome 10.1 IFNG IL10 IL6
25 hepatitis 10.1 IFNG IL10 IL6
26 erb-duchenne and dejerine-klumpke palsies 10.1 IFNG IL10 IL6
27 plummer's disease 10.1 IFNG IL10 IL6
28 usher syndrome, type 2a 10.1 IFNG IL10 IL6
29 orbital osteomyelitis 10.1 IFNG IL10 IL6
30 disease of mental health 10.1 IFNG IL10 IL6
31 follicular adenoma 10.1 IFNG IL10 IL6
32 myiasis 10.1 IFNG IL10 IL6
33 causalgia 10.1 IFNG IL10 IL6
34 depressed scar 10.1 IFNG IL10 IL6
35 mansonelliasis 10.1 IFNG IL10 IL6
36 burns 10.1 IFNG IL10 IL6
37 classic type lipoma 10.1 IFNG IL10 IL6
38 anterior foramen magnum meningioma 10.1 IFNG IL10 IL6
39 blue toe syndrome 10.1 IFNG IL10 IL6
40 clostridium difficile colitis 10.1 IFNG IL6
41 parasitic protozoa infectious disease 10.1 IFNG IL10 IL6
42 hallucinogen dependence 10.1 IFNG IL10 IL6
43 keratomalacia 10.1 IFNG IL10 IL6
44 nonspecific interstitial pneumonia 10.1 IFNG IL10 IL6
45 pulmonary tuberculosis 10.1 IFNG IL10 IL6
46 sclerosing adenosis of breast 10.1 IFNG IL10 IL6
47 osteodysplasty precocious of danks mayne and kozlowski 10.1 IFNG IL10
48 neonatal jaundice 10.1 IFNG IL10 IL6
49 foodborne botulism 10.1 IFNG IL10 IL6
50 pigmentation disease 10.1 IFNG IL10 IL6

Graphical network of the top 20 diseases related to Hand, Foot and Mouth Disease:



Diseases related to Hand, Foot and Mouth Disease

Symptoms & Phenotypes for Hand, Foot and Mouth Disease

Symptoms:

12
  • fever
  • poor appetite
  • malaise
  • sore throat
  • painful sores in the mouth
  • skin rash on the palms of the h

Drugs & Therapeutics for Hand, Foot and Mouth Disease

Drugs for Hand, Foot and Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
2
Sorafenib Approved, Investigational Phase 4,Phase 2 284461-73-0 216239 406563
3
Infliximab Approved Phase 4 170277-31-3
4
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
7
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
8
4-Aminopyridine Approved Phase 4,Phase 2 504-24-5 1727
9
Ribavirin Approved Phase 4 36791-04-5 37542
10
Sunitinib Approved, Investigational Phase 4 341031-54-7, 557795-19-4 5329102
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
12
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 59-67-6 938
13
Nicotinamide Approved, Nutraceutical Phase 4,Phase 2,Phase 1 98-92-0 936
14
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
15
Thiamine Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-43-8 1130
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
17 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
18 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
19 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
20 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
21 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
22 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
23 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Analgesics Phase 4,Phase 3,Phase 2
25 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
26 Angiogenesis Inhibitors Phase 4,Phase 3
27 Angiogenesis Modulating Agents Phase 4,Phase 3
28 Anti-Infective Agents Phase 4,Phase 2,Phase 1
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2
32 Immunosuppressive Agents Phase 4,Phase 3
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
34 Diflucortolone Phase 4
35 Diflucortolone valerate Phase 4
36 Nicotinic Acids Phase 4,Phase 2,Phase 1
37 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2
38 Antiemetics Phase 4,Phase 2
39 Antineoplastic Agents, Hormonal Phase 4
40 Autonomic Agents Phase 4,Phase 2
41 Folic Acid Antagonists Phase 4,Phase 3
42 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
43 glucocorticoids Phase 4,Phase 2
44 Hematinics Phase 4,Phase 2
45 Hormone Antagonists Phase 4,Phase 2
46 Hormones Phase 4,Phase 2
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
48 Methylprednisolone acetate Phase 4,Phase 2
49 Methylprednisolone Hemisuccinate Phase 4,Phase 2
50 Neuroprotective Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 83)
id Name Status NCT ID Phase
1 Apremilast in Palmo-Plantar Psoriasis Completed NCT02400749 Phase 4
2 Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients Completed NCT01098760 Phase 4
3 Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA) Completed NCT01308255 Phase 4
4 Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease Recruiting NCT02328651 Phase 4
5 Thiamin Deficiency in Obese Thai Children Recruiting NCT02464865 Phase 4
6 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Recruiting NCT02555748 Phase 4
7 The Phase IVb of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Children Active, not recruiting NCT03001986 Phase 4
8 The Phase IVa of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) Active, not recruiting NCT02999828 Phase 4
9 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Active, not recruiting NCT02208050 Phase 4
10 Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months Not yet recruiting NCT02889497 Phase 4
11 Standard Versus Continuous Capecitabine in Advanced Breast Cancer Unknown status NCT00418028 Phase 2, Phase 3
12 Topical 5-ALA Photodynamic Therapy for the Treatment of Verruca Vulgaris Unknown status NCT00155584 Phase 3
13 Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis Unknown status NCT00811005 Phase 3
14 An Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT01507857 Phase 3
15 Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT01636245 Phase 3
16 A Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months Completed NCT01508247 Phase 3
17 A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children Completed NCT01569581 Phase 3
18 A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine). Completed NCT00661102 Phase 3
19 Caphosol in Oral Mucositis Due to Targeted Therapy Completed NCT01265810 Phase 3
20 Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX Completed NCT01039688 Phase 3
21 A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate Completed NCT00847613 Phase 3
22 Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer Completed NCT00296036 Phase 3
23 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3
24 Study of Pyridoxine for Hand-Foot Syndrome Completed NCT00446147 Phase 3
25 RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes Completed NCT00379769 Phase 3
26 Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Recruiting NCT03023540 Phase 3
27 Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) Active, not recruiting NCT02579759 Phase 3
28 S-1 Versus Capecitabine in the First Line Treatment of MCC Patients. Active, not recruiting NCT01918852 Phase 3
29 Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer Terminated NCT00305643 Phase 3
30 Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer Terminated NCT00486213 Phase 3
31 Immunochemotherapy for Metastatic Renal Cell Carcinoma Unknown status NCT00226798 Phase 2
32 Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia Unknown status NCT01868750 Phase 2
33 Magnesium Sulphate for Severe Hand, Foot and Mouth Disease in Vietnam Completed NCT01940250 Phase 2
34 A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants Completed NCT01512706 Phase 2
35 A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old Completed NCT02777411 Phase 2
36 A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01399853 Phase 2
37 A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Completed NCT01734408 Phase 2
38 Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Completed NCT01465802 Phase 2
39 A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. Completed NCT00454636 Phase 2
40 Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) Completed NCT01915602 Phase 2
41 A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain Completed NCT00375960 Phase 2
42 Herbal Preparation Used as Adjuvant Therapy on Diabetic Ulcers Completed NCT00393510 Phase 2
43 A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy Completed NCT01589432 Phase 2
44 Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia Completed NCT00824512 Phase 2
45 A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke Completed NCT01605825 Phase 2
46 Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis Recruiting NCT02467504 Phase 2
47 Improving Autonomic Function and Balance in Diabetic Neuropathy Recruiting NCT01864460 Phase 2
48 ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy Recruiting NCT02874651 Phase 2
49 Phase II Study of Perindopril and Regorafenib in mCRC Recruiting NCT02651415 Phase 2
50 Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients Active, not recruiting NCT01234402 Phase 2

Search NIH Clinical Center for Hand, Foot and Mouth Disease

Cochrane evidence based reviews: hand, foot and mouth disease

Genetic Tests for Hand, Foot and Mouth Disease

Anatomical Context for Hand, Foot and Mouth Disease

MalaCards organs/tissues related to Hand, Foot and Mouth Disease:

39
Skin, Testes, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Hand, Foot and Mouth Disease:

18
Skin

Publications for Hand, Foot and Mouth Disease

Articles related to Hand, Foot and Mouth Disease:

(show top 50) (show all 335)
id Title Authors Year
1
Proximal onycholysis as a complication of hand, foot, and mouth disease. ( 28083877 )
2017
2
The exposure-response relationship between temperature and childhood hand, foot and mouth disease: A multicity study from mainland China. ( 28069250 )
2017
3
Temporal and spatial analysis of hand, foot, and mouth disease in relation to climate factors: A study in the Mekong Delta region, Vietnam. ( 28063653 )
2017
4
A Case-control Study on Risk Factors for Severe Hand, Foot and Mouth Disease. ( 28084311 )
2017
5
Nonlinear and Interactive Effects of Temperature and Humidity on Childhood Hand, Foot and Mouth Disease in Hefei, China. ( 27276180 )
2016
6
Molecular epidemiology of the enteroviruses associated with hand, foot and mouth disease/herpangina in Dongguan, China, 2015. ( 27654666 )
2016
7
Study of the epidemiology and etiological characteristics of hand, foot, and mouth disease in Suzhou City, East China, 2011-2014. ( 27146138 )
2016
8
Development and evaluation of a non-ribosomal random PCR and next-generation sequencing based assay for detection and sequencing of hand, foot and mouth disease pathogens. ( 27388326 )
2016
9
Socio-ecological factors and hand, foot and mouth disease in dry climate regions: a Bayesian spatial approach in Gansu, China. ( 27329324 )
2016
10
Determinants of the Transmission Variation of Hand, Foot and Mouth Disease in China. ( 27701445 )
2016
11
Epidemiological Features of Hand, Foot and Mouth Disease during the Period of 2008-14 in Wenzhou, China. ( 27765889 )
2016
12
Prolonged Breastfeeding Is Associated With Lower Risk Of Severe Hand, Foot And Mouth Disease In Chinese Children. ( 26650113 )
2016
13
Changes of circulating Th22 cells in children with hand, foot, and mouth disease caused by enterovirus 71 infection. ( 28030850 )
2016
14
An Outbreak of Kingella kingae Infections Complicating a Severe Hand, Foot, And Mouth Disease Outbreak in Nice, France, 2016. ( 28002358 )
2016
15
Early risk indicators for hand, foot and mouth disease clusters in China. ( 27684557 )
2016
16
The Effects of Weather Factors on Hand, Foot and Mouth Disease in Beijing. ( 26755102 )
2016
17
Hand, Foot and Mouth Disease in Hong Kong: A Time-Series Analysis on Its Relationship with Weather. ( 27532865 )
2016
18
Hand Foot and Mouth Disease Like Illness in Office Practice. ( 27943150 )
2016
19
Short-term effects of meteorological factors on hand, foot and mouth disease among children in Shenzhen, China: Non-linearity, threshold and interaction. ( 26386448 )
2016
20
A literature review and case report of hand, foot and mouth disease in an immunocompetent adult. ( 26975350 )
2016
21
EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). ( 26732723 )
2016
22
Hand, foot and mouth disease: an overview of clinical features in adult patients. ( 27859744 )
2016
23
Two Genotypes of Coxsackievirus A2 Associated with Hand, Foot, and Mouth Disease Circulating in China since 2008. ( 28030650 )
2016
24
Enterovirus-related diarrhoea in Guangdong, China: clinical features and implications in hand, foot and mouth disease and herpangina. ( 26983856 )
2016
25
Diagnostic uncertainty of herpangina and hand-foot-and-mouth disease and its impact on national enterovirus syndromic monitoring. ( 26593706 )
2016
26
Neurological complications and risk factors of cardiopulmonary failure of EV-A71-related hand, foot and mouth disease. ( 27001010 )
2016
27
Age patterns and transmission characteristics of hand, foot and mouth disease in China. ( 27871252 )
2016
28
Effects of Meteorological Parameters and PM10 on the Incidence of Hand, Foot, and Mouth Disease in Children in China. ( 27171104 )
2016
29
Ambulatory Pediatric Surveillance of Hand, Foot and Mouth Disease as Signal of an Outbreak of Coxsackievirus A6 Infections, France, 2014-2015. ( 27767012 )
2016
30
Immunodominant IgM and IgG Epitopes Recognized by Antibodies Induced in Enterovirus A71-Associated Hand, Foot and Mouth Disease Patients. ( 27806091 )
2016
31
Diagnosis of human enteroviruses that cause hand, foot and mouth disease. ( 27042876 )
2016
32
Clinicopathologic analysis of atypical hand, foot, and mouth disease in adult patients. ( 28027826 )
2016
33
Detecting spatial-temporal cluster of hand foot and mouth disease in Beijing, China, 2009-2014. ( 27184561 )
2016
34
Inhibition of enterovirus VP4 myristoylation is a potential antiviral strategy for hand, foot and mouth disease. ( 27520386 )
2016
35
Hand-Washing: The Main Strategy for Avoiding Hand, Foot and Mouth Disease. ( 27322307 )
2016
36
The Epidemiology of Hand, Foot and Mouth Disease in Asia: A Systematic Review and Analysis. ( 27273688 )
2016
37
Coxsackievirus associated hand, foot and mouth disease in an adult. ( 27634973 )
2016
38
Transmission of Hand, Foot and Mouth Disease and Its Potential Driving Factors in Hong Kong. ( 27271966 )
2016
39
Late-onset acute graft-versus-host disease mimicking hand, foot, and mouth disease. ( 27990387 )
2016
40
Characterization of enterovirus 71 infection and associated outbreak of Hand, Foot, and Mouth Disease in Shawo of China in 2012. ( 27941929 )
2016
41
Exacerbation of bullous pemphigoid after hand, foot, and mouth disease treated with rituximab. ( 27051813 )
2016
42
Atypical hand, foot and mouth disease in adults associated with coxsackievirus A6: a clinico-pathologic study. ( 27445155 )
2016
43
Comparisons between mild and severe cases of hand, foot and mouth disease in temporal trends: a comparative time series study from mainland China. ( 27769194 )
2016
44
Risk factors for death in children with severe hand, foot, and mouth disease in Hunan, China. ( 27195893 )
2016
45
B1c genetic subtype of coxsackievirus A16 associated with hand, foot and mouth disease in Andaman Islands, India. ( 27496517 )
2016
46
Boosted regression tree model-based assessment of the impacts of meteorological drivers of hand, foot and mouth disease in Guangdong, China. ( 26930310 )
2016
47
Assessment of temperature effect on childhood hand, foot and mouth disease incidence (0-5years) and associated effect modifiers: A 17 cities study in Shandong Province, China, 2007-2012. ( 26891011 )
2016
48
Susceptibility of inhibitors against 3C protease of coxsackievirus A16 and enterovirus A71 causing hand, foot and mouth disease: A molecular dynamics study. ( 27668727 )
2016
49
Impact of temperature variability on childhood hand, foot and mouth disease in Huainan, China. ( 26708474 )
2016
50
Effect of integrated Chinese and Western medicine therapy on severe hand, foot and mouth disease: A prospective, randomized, controlled trial. ( 27392481 )
2016

Variations for Hand, Foot and Mouth Disease

Expression for Hand, Foot and Mouth Disease

Search GEO for disease gene expression data for Hand, Foot and Mouth Disease.

Pathways for Hand, Foot and Mouth Disease

Pathways related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 C4A IFNG IL10 IL6
2
Show member pathways
12.35 IFNG IL10 IL17F IL6
3
Show member pathways
12.33 IFNG IL10 IL17F IL6
4
Show member pathways
12.12 IFNG IL17F IL6
5 12.02 IFNG IL10 IL6
6
Show member pathways
11.98 IFNG IL10 IL6
7 11.95 C4A IL10 IL6
8 11.79 IFNG IL10 IL6
9 11.77 IL10 IL17F IL6
10
Show member pathways
11.73 IFNG IL10 IL6
11
Show member pathways
11.66 IFNG IL17F IL6
12 11.62 IFNG IL10 IL6
13 11.49 IFNG IL10 IL6
14 11.46 C4A IL10 IL6
15 11.37 IFNG IL10 IL6
16 11.25 C4A IL10 SELPLG
17 11.19 IFNG OAS1
18 11.15 IL10 IL6
19
Show member pathways
11.13 IFNG IL10 IL6 OAS1
20 11.12 IFNG IL10 IL6
21 11.1 IFNG IL6
22 11 IFNG IL10
23 10.88 IFNG IL10 IL6
24 10.61 IFNG IL10 IL6

GO Terms for Hand, Foot and Mouth Disease

Cellular components related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 C4A CA6 IFNG IL10 IL17F IL6
2 extracellular space GO:0005615 9.1 C4A CA6 IFNG IL10 IL17F IL6

Biological processes related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.76 IFNG IL10 IL6 OAS1
2 defense response to virus GO:0051607 9.65 IFNG IL6 OAS1
3 inflammatory response GO:0006954 9.62 C4A IL10 IL17F IL6
4 cellular response to lipopolysaccharide GO:0071222 9.58 IFNG IL10 IL6
5 negative regulation of growth of symbiont in host GO:0044130 9.43 IFNG IL10
6 cellular response to hepatocyte growth factor stimulus GO:0035729 9.37 IL10 IL6
7 positive regulation of protein import into nucleus, translocation GO:0033160 9.26 IFNG IL6
8 positive regulation of MHC class II biosynthetic process GO:0045348 9.16 IFNG IL10
9 neutrophil apoptotic process GO:0001781 8.96 IFNG IL6
10 defense response to protozoan GO:0042832 8.8 IFNG IL10 IL6

Molecular functions related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IFNG IL10 IL17F IL6

Sources for Hand, Foot and Mouth Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....